EF Hutton Maintains Buy on Hoth Therapeutics, Lowers Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Elemer Piros maintains a 'Buy' rating on Hoth Therapeutics (NASDAQ:HOTH) but lowers the price target from $12 to $7.5.
September 14, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, EF Hutton maintains a 'Buy' rating on Hoth Therapeutics, indicating continued confidence in the company's potential.
The lowered price target might initially cause some negative sentiment among investors. However, the maintained 'Buy' rating indicates that EF Hutton still sees potential in Hoth Therapeutics, which could balance out the initial negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100